Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1CNS 1Breast 1

Conditions

Carcinoma, Hepatocellular 19Carcinoma, Renal Cell 13Parkinson Disease 4, Autosomal Dominant Lewy Body 10Endometrial Neoplasms 6Neoplasms 4Biliary Tract Neoplasms 4Neuroendocrine Tumors 3Melanoma 3Liver Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2von Hippel-Lindau Disease 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Penile Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Kidney Neoplasms 1Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1

Interventions

Gemcitabine 57130-nm albumin-bound paclitaxel 35Specimen Handling 26Magnetic Resonance Spectroscopy 21Albumin-Bound Paclitaxel 21Fluorouracil 20Leucovorin 19Irinotecan 19Oxaliplatin 17Biopsy 17Taxes 16pembrolizumab 13Cyclophosphamide 11Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8Nivolumab 7Carboplatin 7irinotecan sucrosofate 6durvalumab 6dehydroftorafur 6Radiosurgery 6Pemetrexed 6olaparib 5Ipilimumab 5Erlotinib Hydrochloride 5trastuzumab deruxtecan 4aldesleukin 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × lenvatinib × 90 days × Clear all
NCT03797326 2026-05-04

LEAP-005

Merck Sharp & Dohme LLC

Phase 2 Completed
611 enrolled 27 charts
BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04887805 2026-04-29

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
28 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡